Antag Therapeutics is set to unveil pivotal clinical and preclinical data on AT7687, a first-in-class GIP receptor antagonist peptide, during the upcoming 2026 Scientific Sessions of the American Diabetes Association. Scheduled for June 5-8 in New Orleans, the presentation will include an oral report on first-in-human results demonstrating that AT7687 is well tolerated and effective for once-weekly subcutaneous injection in individuals with obesity. Additionally, a poster will detail preclinical findings showcasing the synergistic effects of AT7687 combined with cagrilintide, revealing significant weight loss and enhanced insulin sensitivity in obese insulin-resistant non-human primates.

The implications of these findings are substantial, particularly in the context of obesity management and metabolic health. The data suggest that AT7687 not only facilitates weight loss but also improves body composition and insulin sensitivity, critical factors in combating obesity-related comorbidities. The completion of the Phase 1 trial positions AT7687 favorably for the anticipated Phase 2a studies, which are projected to commence in mid-2026. This timeline aligns with the increasing urgency to address obesity as a global health crisis, particularly given its association with aging and longevity.

The successful development of AT7687 could shift current paradigms in obesity treatment, potentially leading to more effective therapeutic strategies that target metabolic dysfunction at its root. Furthermore, the recent €80 million Series A financing led by Versant Ventures underscores the growing interest and investment in innovative approaches to obesity and metabolic disease, which may accelerate drug development timelines and enhance collaboration within the biotech sector.

Source: longevity.technology